Development of a novel lead that targets M. tuberculosis polyketide synthase 13

Published Date:

11/30/2018

Source:

Cell

Authors:

Aggarwal A, Parai MK, Shetty N, Wallis D, Woolhiser L, Hastings C, Dutta NK, Galaviz S, Dhakal RC, Shrestha, R, Wakabayashi S, Walpole C, Matthews D, Floyd D, Scullion P, Riley J, Epemolu O, Norval S, Snavely T, Robertson GT, Rubin EJ, Ioerger TR, Sirgel EA, van der Merwe R, van Helden PD, Keller P, Böttger EC, Karakousis PC, Lenaerts A.J, Sacchettini JC

External link

Original Article

Widespread resistance to first-line TB drugs is a major problem that will likely only be resolved through the development of new drugs with novel mechanisms of action. We have used structure-guided methods to develop a lead molecule that targets the thioesterase activity of polyketide synthase Pks13, an essential enzyme that forms mycolic acids, required for the cell wall of Mycobacterium tuberculosis. Our lead, TAM16, is a benzofuran class inhibitor of Pks13 with highly potent in vitro bactericidal activity against drug-susceptible and drug-resistant clinical isolates of M. tuberculosis. In multiple mouse models of TB infection, TAM16 showed in vivo efficacy equal to the first-line TB drug isoniazid, both as a monotherapy and in combination therapy with rifampicin. TAM16 has excellent pharmacological and safety profiles, and the frequency of resistance for TAM16 is ∼100-fold lower than INH, suggesting that it can be developed as a new antitubercular aimed at the acute infection.

Events

«

August 2019

»
S
M
T
W
T
F
S
·
·
·
·
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

Projects

Impact of diabetes on TB treatment outcomes...

This is a study to prospectively enroll and follow TB patients co-infected with diabetes and TB patients without diabetes...

Read More

Understanding and Improving the Effectiveness...

The goal of this project is to construct a mathematical model of the laboratory network for diagnosis of infectious diseases in...

Read More

FlexDx-TB: A flexible, user-friendly model of...

We have developed a web-based model that allows decision-makers to input local epidemiological and economic values and receive...

Read More

Assessing the social value of novel regimens...

We are collaborating with investigators from the Berman Bioethics Institute to develop novel techniques for economic evaluation...

Read More